Novartis responds to concerns raised about the social & environmental impacts of its business practices
On 2 April, the German-Swiss newspaper TagesWoche published an article about Novartis' decision to name Shannon Klinger chief of ethics and compliance and elevate the function to be part of the executive board following concerns raised about its patent policy and access to medicine as well as environmental impacts. We invited Novartis to respond to the TagesWoche article and asked how the company mitigates the social and environmental impacts of its business practices; response provided below.
Note: TagesWoche article only available in German.
All components of this story
At Novartis, corporate responsibility (CR) is central to how we run our business. Our CR strategy supports our company mission to discover new ways to improve and extend people’s lives and our vision to be a trusted leader in changing the practice of medicine. We focus our CR work in two key areas: expanding access to healthcare and doing business responsibly.
To achieve our mission, we have a responsibility to use our expertise and skills to address the needs of underserved populations. We work to improve the affordability and availability of our medicines by pioneering sustainable and scalable access models. And we seek effective partnerships to help deliver treatments and quality care to as many people as possible. Read more about our access-to-healthcare programs on our website...
As a responsible company, we are committed to conducting our business in a manner that respects the rights and dignity of all people. Our full Modern Slavery Statement is available on our website. We are also fully committed to a cleaner environment for the benefit of our patients, our investors and our communities. More details on our approach to environmental sustainability are available on our website...
- Related stories: Novartis responds to concerns raised about the social & environmental impacts of its business practices
- This is a response from the following companies: Novartis
TagesWoche article available in German here.